Sartar’s novel anti-GIST product
Chairman of the Board. Adjunct Professor of Cancer Biology, whose research focuses on rare cancers.
Professor of Oncology and the European key opinion leader of GIST therapies.
Ph.D. student, whose research focus is on new therapeutic targets in GIST.
An innovative Professor of Molecular Precision Medicine.
Seasoned biotech expert and founder of two biotech companies.
Upcoming events and news
Sartar will give a presentation at the 2nd KYOTO−SPARK Symposium. http://www.kyoto-spark.med.kyoto-u.ac.jp/newsen/20171227161216/
The Vice-Chairman of the Board and a co-founder the Sartar Therapeutics Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation. Congratulations Heikki on your new appointment!
Sartar was awarded a USA patent for use of anagrelide in cancer therapy.
Sartar Therapeutics participated to the HealthBIO pitching competition and won it. http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/
Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November. https://ebdgroup.knect365.com/bioeurope/
Sartar participates in HealthBIO partnering event. http://www.healthbio.fi/